Peginterferon alfa-2b

This page contains recent news articles, when available, and an overview of Peginterferon alfa-2b but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

Overview:

Peginterferon alfa-2b (when available)

Pharmacology and use:
Upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing. Interferon alpha also induce the synthesis of several key antiviral mediators, including 2'-5' oligoadenylate synthetase (2'-5' A synthetase) and protein kinase R. For treatment of hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma

Mechanism Of Action:
Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.

News Articles on Peginterferon alfa-2b

Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of ...  -  ‎Aug 5, 2009‎
We compared the rate of sustained virologic response and the safety and adverse-event profiles between the peginterferon alfa-2b regimens and between the New England Journal of Medicine (subscription)

Genetic variation in IL28B predicts hepatitis C treatment-induced ...  -  ‎Aug 17, 2009‎
361, 580–593 (2009) Muir, AJ, Bornstein, JD & Killenberg, PG Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and Nature.com (subscription)

Team Uses GWAS to ID Biomarker for Hepatitis C Treatment Response  -  ‎Aug 17, 2009‎
Schering-Plough, which markets peginterferon alfa-2b under the brand name Peg-Intron, funded the study and Goldstein and several other authors on the paper GenomeWeb Daily News

Federer y Murray disputarán una de las semifinales del Masters de ...  -  ‎Aug 21, 2009‎
...study compared treatment with two PEG-INTRONВ®/ribavirin regimens INTRON (peginterferon alfa-2b, recombinant) 1.5 mcg/kg SC once weekly (QW)/ribavirin La Prensa Gráfica

Current hepatitis C treatments work equally well  -  ‎Aug 8, 2009‎
...treatments: a standard dose of peginterferon alfa-2b, a low dose of peginterferon alfa-2b, or peginterferon alfa-2a, each in combination with ribavirin. Science Centric

�?�乙二醇干扰素α-2b 或α-2a�?��?�利巴韦林治疗丙型�?炎  -  ‎Aug 28, 2009‎
...�?�考文献：McHutchison.JG, et al. Peginterferon Alfa-2b orAlfa-2a with Ribavirin for Treatment of Hepatitis C Infection.N Engl J Med 2009;361:580-93. 三九健康网

Natural Course of Treated and Untreated Chronic HCV Infection ...  -  ‎Jun 18, 2009‎
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Medscape

2013년 C형간염 시장 3배�?��? 성장  -  ‎Jun 23, 2009‎
...현재 미국�?� 경우 C형 간염 치료제로 '페가시스'(Pegasys, peginterferon alfa-2a), '페그�?�트론'(PegIntron, peginterferon alfa-2b), '리바비린'(ribavirin)�?� 애용 디지틀보사

Schering-Plough Europe Withdraws Its Marketing Authorisation ...  -  18 Mar 2009
Schering-Plough) of its decision to withdraw its application for a centralised marketing authorisation for the medicine Cylatron (peginterferon alfa-2b), PharmaLive.com (press release)

Schering-Plough Europe Withdraws Its Marketing Authorisation ...  -  ‎Mar 17, 2009‎
...marketing authorisation for the medicine Cylatron (peginterferon alfa-2b), 200 micrograms /0.5 ml, 300 micrograms /0.5 ml and 600 micrograms/0.5 ml. Medical News Today (press release)

FDA Approves Peginterferon/Ribavirin Combo for Treatment ...  -  ‎Mar 11, 2009‎
..."Based on a patient's treatment history, physicians can identify which patients may be right for retreatment with [peginterferon alfa-2b/ribavirin] DG News

Schering-Plough Says FDA Approves Label Expansion for Pegintron ...  -  ‎Mar 11, 2009‎
...(SGP: News ), a global pharmaceuticals company, said US Food and Drug Administration or FDA approved new labeling for Pegintron or peginterferon alfa-2b and RTT News

Committee For Medicinal Products For Human Use Summary Of Positive ...  -  Jan 23, 2009
...capsule intended for the treatment of chronic hepatitis C infection as part of a combination regimen with peginterferon alfa-2b or interferon alfa-2b. PharmaLive.com (press release),

PEGASYS(R) Proven Effective as Hepatitis C Treatment for Latino ...  -  Jan 14, 2009
...single-center Italian studies with PEGASYS have shown reproducible efficacy in HCV patients with genotype 1 and 4 compared to peginterferon alfa-2b. PR Newswire (press release),

What's the evidence for pegylated interferon plus ribavirin?  -  Jan 21, 2009
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. guardian.co.uk,

PEGASYS® Proven Effective as Hepatitis C Treatment for Latino ...  -  Jan 16, 2009
...single-center Italian studies with PEGASYS have shown reproducible efficacy in HCV patients with genotype 1 and 4 compared to peginterferon alfa-2b. PR-USA.net (press release),

New products: Rx, generic, OTC  -  Jan 29, 2009
Schering-Plough announced the FDA has granted marketing approval to Pegintron (peginterferon alfa-2b) and Rebetol (ribavirin, USP) combination therapy for Modern Medicine,

Schering-Plough Completes Enrollment of Boceprevir Registration ...  -  Jan 27, 2009
In that study, a 48-week boceprevir regimen achieved a 75 percent SVR rate in patients who received 4 weeks of PEGINTRON(TM) (peginterferon alfa-2b) and PR Newswire (press release),

FDA Approvals: Lusedra and Pegintron/Rebitol  -  Dec 20, 2008
Describe the appropriate use of peginterferon alfa-2b and ribavirin combination treatment for chronic hepatitis C in the pediatric population. Medscape

European Commission Approves New Indication for Peginterferon Alfa-2a  -  Dec 4, 2008
The study demonstrated that in patients who were prior nonresponders to peginterferon alfa-2b (PegIntron) plus ribavirin, 72 weeks of retreatment with DG News

Roche wins European approval for hepatitis drug  -  Dec 5, 2008
...the chance of achieving a cure, compared to 48 weeks, in patients who were prior non-responders to PegIntron (peginterferon alfa-2b) and ribavirin. Pharmaceutical Business Review

Schering-Plough Announces FDA Approval of PEGINTRON(TM) and ...  -  Dec 12, 2008
...today announced that the US Food and Drug Administration (FDA) has granted marketing approval to PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) MarketWatch

European Commission Approval of New Indication for Roche's Pegasys ...  -  Dec 4, 2008
...chance of a achieving a cure, compared to 48 weeks, in patients who were prior non-responders to PegIntron(TM) (peginterferon alfa-2b) and ribavirin. ITNews,

Medscape News CME Index  -  Dec 21, 2008
...fospropofol disodium injection (Lusedra) and a new indication for combination therapy with peginterferon alfa-2b and ribavirin (Pegintron/Rebitol). Medscape

Burden of Hepatitis C Infection: Realities and Challenges  -  Dec 4, 2008
HCV SPRINT-1: Boceprevir plus peginterferon alfa-2b/ribavirin for treatment of genotype 1 chronic hepatitis C in previously untreated patients. Hepatology. Medscape

Zulassungserweiterung: Pegyliertes Interferon auch für ...  -  Dec 18, 2008
Die Studie zeigte bei Patienten, die auf eine Therapie mit Peginterferon alfa-2b (PegIntron®) und Ribavirin zuvor nicht angesprochen hatten, Apotheker Zeitung,

New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained ...  -  Nov 1, 2008
Randomized study comparing peginterferon-alfa-2a plus ribavirin and peginterferon-alfa-2b plus ribavirin in naive patients with chronic hepatitis C: final MarketWatch

Approach to the Treatment of HCV Nonresponders  -  Oct 28, 2008
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Medscape (registration)

New Study Shows That Pegasys Regimen Provides Higher Cure Rates ...  -  Nov 1, 2008
The Milan Safety Tolerability (MIST) Study randomly assigned 431 patients to receive Pegasys or peginterferon alfa-2b, both in combination with ribavirin. PresseEcho.de (Pressemitteilung),

PEGASYS Regimen Provides Higher Sustained Virological Response ...  -  Nov 3, 2008
SVR rates in patients treated with PEGASYS/ribavirin as compared to those treated with peginterferon alfa-2b (PegIntron)/ribavirin (66 percent vs. eMaxHealth.com,

Renewed Hope for a Cure: Extending Pegasys Treatment to 72 Weeks ...  -  Nov 3, 2008
...the 72-week regimen of Pegasys and Copegus is the preferred treatment duration for non-responders to previous peginterferon alfa-2b/ribavirin therapy. PR-CANADA.net (press release),

Comunicato stampa Schering-Plough  -  Nov 18, 2008
Boceprevir Plus Peginterferon alfa-2b/Ribavirin for Treatment of Genotype 1 Chronic Hepatitis C in Previously Untreated Patients: Interim Results from the Associazione EpaC Onlus,

Roche/Pegasys est plus durablement efficace (hépatite C)  -  Nov 2, 2008
L'étude "Milan Safety Tolerability Study" (MIST) a porté sur 431 patients qui ont été traités avec Pegasys ou PegIntron (peginterferon alfa 2b), Romandie.com,

Roche/Pegasys zeigt bessere nachhaltige Wirksamkeit bei Hepatitis ...  -  Nov 2, 2008
In der vergleichenden Studie - Milan Safety Tolerability Study (MIST) - wurden 431 Patienten Pegasys oder PegIntron (peginterferon alfa 2b), Swissinfo,

Tests virologiques dans les hépatites B et C  -  16 Sep 2008
Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment Hépato-Gastro (Abonnement),

New Directions in Hepatitis C Therapy: The Evolving Therapeutic ...  -  Sep 5, 2008
Interim results from HCV SPRINT-1: RVR/EVR from phase 2 study of boceprevir plus pegINTRON (peginterferon alfa-2b)/ribavirin in treatment-naive subjects Medscape (subscription)

Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III ...  -  Jul 11, 2008
Peginterferon alfa-2b is not approved for treatment of melanoma in either the US or EU. The study was designed to assess the efficacy and safety of Biloxi Sun Herald,

Schering-Plough presents positive results from Phase III melanoma ...  -  Jul 14, 2008
Researchers randomized patients to either peginterferon alfa-2b adjuvant treatment (n=627) or observation only (n=629) within 70 days of regional lymph node Trading Markets (press release),

Top-Line Results of Boceprevir Phase II Study Showed High Rate of ...  -  Aug 4, 2008
...the end of treatment (SVR 12) was 74 percent (ITT) in patients who received 4 weeks of PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, CNNMoney.com (press release)

Schering-Plough Reports Positive Results From Phase II Hepatitis Study  -  Aug 5, 2008
...who received four weeks of Pegintron (peginterferon alfa-2b) and Rebetol (ribavirin, USP) prior to the addition of boceprevir (800mg TID) (P/R lead-in), RedOrbit,

Hépatologie « transversale » : l’exemple de l’infection par le ...  -  Jul 19, 2008
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004 ; 18 : 27-36. Hépato-Gastro (Abonnement),

Ongoing Challenges in the Management of Chronic Hepatitis C  -  Jun 30, 2008
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Medscape (subscription)

EU Approval For Roche's Pegasys Personalises Treatment For A ...  -  Jun 27, 2008
Dalgard O, Bjoro K, Ring-Larsen H, Verbaan H. Peginterferon alfa-2b and ribavirin for 14 or 24 weeks in patients with HCV genotype 2 or 3 and rapid Medical News Today (press release),

About 60 Clinical Studies Regarding Schering-Plough's Oncology ...  -  May 30, 2008
INTRON(R) A and peginterferon alfa-2b: Data will be featured in more than 10 abstracts, including five poster discussions and five oral presentations. Earthtimes (press release),

Positive Findings in Treatment for Advanced Hepatitis C  -  May 6, 2008
MILAN, ITALY – The hepatitis C therapy peginterferon alfa-2b, when given as low-dose maintenance therapy, can prevent disease progression in certain EndoNurse,

Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis ...  -  May 15, 2008
Clearance of HCV at 5 Year Follow-Up for Peginterferon Alfa-2b with or without Ribavirin Is Predicted by Sustained Virologic Response at 24 Weeks Earthtimes (press release),

Schering-Plough To Initiate Phase III Studies With HCV Protease ...  -  May 21, 2008
...placebo-controlled studies will evaluate the efficacy of boceprevir in combination with PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, Earthtimes (press release),

Schering-Plough to Initiate Two Phase III Hepatitis Studies  -  May 22, 2008
The two randomized, double-blind, placebo-controlled studies will evaluate the efficacy of boceprevir in combination with Pegintron (peginterferon alfa-2b) RedOrbit,

Schering-Plough Reports Financial Results for First Quarter of 2008  -  23 Apr 2008
...(Announced March 18) -- Gained FDA approval of label revisions for PEGINTRON (peginterferon alfa-2b) and REBETOL (ribavirin, USP) combination therapy for PR Newswire (press release),

Roche Sees Softness in US Hepatitis C Market  -  Apr 21, 2008
...(peginterferon alfa-2b) and Rebetol (ribavirin). Results from the study found sustained virologic responses were similar for the combination therapies. FDA news (subscription),

FDA Approvals: Rotarix and PegIntron/Rebetol  -  Apr 10, 2008
Identify new recommendations for ribavirin/peginterferon alfa-2b therapy in the treatment of chronic hepatitis C virus infection. Medscape (subscription)

Pegintron(TM) Plus Weight-Based Rebetol(R) Resulted in Higher SVR ...  -  Mar 27, 2008
Peginterferon alfa-2b and Weight-Based or Flat- Dose Ribavirin in Chronic Hepatitis C Patients: A Randomized Trial. Hepatology 2007; 46:971-981. FOXBusiness

Weight-Based Dosing of Ribavirin Improves Hepatitis  -  Apr 18, 2008
Article: "Peginterferon alfa-2b and Weight-Based or Flat-Dose Ribavirin in Chronic Hepatitis C Patients: A Randomized Trial." Jacobson, Ira; Brown, Robert; EndoNurse,

Schering-Plough To Present Data On Chronic Hepatitis C Therapies ...  -  Apr 17, 2008
...(SGP), announced that it would present the final results of the IDEAL study, which evaluated the Pegintron (peginterferon alfa-2b) and Rebetol combination RTT News,

Revised dosing for Pegintron/Rebetol  -  Mar 27, 2008
The FDA has approved label revisions for Schering-Plough’s Pegintron (peginterferon alfa-2b) and Rebetol (ribavirin) combination therapy for chronic Prescribing Reference,

Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data ...  -  Apr 17, 2008
Late-Breaker Parallel Session 16, Saturday, April 26, 4:00 pm Hall A. Colchicine versus peginterferon alfa 2b long term therapy: results of the 4 year Earthtimes,

Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data ...  -  Apr 17, 2008
...announced today that final results of the IDEAL study as well as from several other clinical studies with PEGINTRON(TM) (peginterferon alfa-2b) and SunHerald.com,

Southwest Bancorp Q1 Profit Rises - Quick Facts [OKSB]  -  Apr 17, 2008
...(SGP) on Thursday revealed that final results of the IDEAL study as well as from several other clinical studies with PEGINTRON or peginterferon alfa-2b and RTT News,

The Maybach Financial Group: Schering-Plough Corp. Review in Progress  -  Mar 27, 2008
...(FDA) has approved label revisions for PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL (ribavirin, USP) combination therapy for chronic hepatitis C, Trading Markets (press release),

FDA Postpones Hearing on Use of Pegintron for Skin Cancer  -  Mar 10, 2008
...panels of the US Food and Drug Administration has postponed its planned meeting on the use of Pegintron (Peginterferon alfa-2b) in cases of skin cancer. eFluxMedia

Rebetol Oral Solution  -  Feb 18, 2008
...also as part of a combination regimen with peginterferon alfa-2b (in adults previously untreated or who have failed previous alpha interferon therapy). Irish Medical Times,

SCHERING-PLOUGH CORPORATION - Final Results  -  Feb 12, 2008
25, 2008) -- Announced FDA acceptance for review of the Peg-IFN (peginterferon alfa- 2b) supplemental Biologics License Application, granted Priority Review Trading Markets (press release),

Brand Names/Synonyms:
Peginterferon alfa-2b is also known by the following brand names and/or synonymsInterferon alpha-2 precursor;Interferon alpha-A;LeIF A; PEG-Intron

Drug Category:
Peginterferon alfa-2b is categorized under the following by the FDA: Antiviral Agents; Immunomodulatory Agents; Antineoplastic Agents; interferons (08:18.20)

Dosage Forms:
POWDER FOR SOLUTION

Absorption:
Not Available

Interactions:
Not Available

Chemical IUPAC Name:
PEGylated human interferon alpha 2b

:

Web health.mongabay.com/health

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on health.mongabay.com/health lead to other sites. health.mongabay.com/health does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is health.mongabay.com/health responsible for dead or misdirected links.

IF YOU NEED A LINK/TEXT REMOVED FROM THIS PAGE, PLEASE CONTACT: mongabay (at) gmail.com